Skip to content

The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomised double‐blind placebo‐controlled trial

Research output: Contribution to journalArticlepeer-review

  • Clare A. Whicher
  • Hermione C. Price
  • Peter Phiri
  • Shanaya Rathod
  • Katharine Barnard‐Kelly
  • Dr Ngianga Ii Kandala
  • Kerensa Thorne
  • Carolyn Asher
  • Robert C. Peveler
  • Joanne McCarthy
  • Richard I. G. Holt
Background: People with severe mental illness are 2‐3 times more likely to be overweight and obese than the general population and this is associated with significant morbidity and premature mortality. This study investigated the feasibility and acceptability of using liraglutide 3.0 mg daily to address this problem.

Materials and Methods

Design: Double‐blind, randomised, placebo‐controlled pilot trial.

Setting: Mental health centres and primary care within Southern Health NHS Foundation Trust.

Participants: Adults with schizophrenia, schizoaffective, or first‐episode psychosis prescribed antipsychotic medication who were overweight or obese.

Intervention: Once daily subcutaneous liraglutide or placebo, titrated to 3.0 mg daily, for 6 months.

Primary outcome: recruitment, consent, retention and adherence.

Secondary exploratory outcomes: weight, HbA1c and Brief Psychiatric Rating Scale.

Results: 799 individuals were screened for eligibility. The commonest reasons for exclusion were ineligibility (44%) and inability to make contact (28%). The acceptance rate, as a proportion of all eligible participants, was 12.2%. The commonest stated reason why eligible candidates declined to participate related to the study specific medication and protocol (n= 50). 47 participants were randomised with 79% completing the trial. Participants in the liraglutide arm had lost a mean 5.7±7.9 kg compared with no significant weight change in the placebo group (treatment difference −6.0 kg, p=0.015). BMI, waist circumference and HbA1c reduced in the intervention group.

Conclusions: This study supports the need for a larger randomised controlled trial to evaluate use of liraglutide (maximum dose 3.0 mg daily) in the management of obesity in people with severe mental illness.
Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Early online date16 Feb 2021
DOIs
Publication statusEarly online - 16 Feb 2021

Documents

  • The use of liraglutide 3.0 mg daily

    Rights statement: This is the peer reviewed version of the following article: Whicher, CA, Price, HC, Phiri, P, et al. The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double‐blind, placebo‐controlled trial. Diabetes Obes Metab. 2021, which has been published in final form at https://doi.org/10.1111/dom.14334. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

    Accepted author manuscript (Post-print), 1.6 MB, PDF document

    Due to publisher’s copyright restrictions, this document is not freely available to download from this website until: 16/02/22

Related information

Relations Get citation (various referencing formats)

ID: 26154245